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in demographics and clinical characteristics, patients with high adherence had signiﬁ-
cantly lower total health care costs ($938, p  0.05), primarily due to lower inpatient 
($2,057, p  0.05) and outpatient ($951, p  0.05) costs than patients with low 
adherence. CONCLUSIONS: Higher average daily dose of duloxetine appeared to be 
predictor of high adherence among ﬁbromyalgia patients. High adherence to the 
duloxetine therapy was associated with lower total health care costs.
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OBJECTIVES: To examine the relationship between average daily dose (ADD) of 
duloxetine, medication adherence, and health care costs among ﬁbromyalgia patients. 
METHODS: This study employed a retrospective cohort design to analyze administra-
tive claims database for commercially-insured patients diagnosed with ﬁbromyalgia 
who initiated duloxetine in 2006, with initiation deﬁned as 90-day medication gap. 
The dispense date of the ﬁrst duloxetine prescription ﬁlled was deﬁned as the index 
date. All patients selected were required to have at least 30 days of duloxetine supply 
in the 12 months follow-up period, and those with diabetic peripheral neuropathic 
pain or depression diagnosis during the prior 12 months were excluded. Five cohorts 
were constructed based on ADD: 30 mg, 30 mg, 31–59 mg, 60 mg, and 60 mg. 
Adherence was measured via medication possession ratio (MPR) of duloxetine over 
12-month post-index period, with MPR  0.8 as high adherence. Multivariate regres-
sion models adjusting for differences in demographic and clinical characteristics were 
used to examine the association between ADD, adherence and health care costs. 
RESULTS: The study sample included 4,869 ﬁbromyalgia patients. Three percent of 
patients had an ADD of 30 mg, 12% of 30 mg, 21% of 31–59 mg, 46% of 60 mg, 
and 18% of 60 mg. Approximately one-third of patients had high adherence. Con-
trolling for demographics and clinical characteristics, patients with ADD  30 mg 
(31–59 mg, and 60 mg) were less (more) likely to adhere to duloxetine than those 
with 60 mg (all p  0.05). Compared with patients maintaining an ADD of 60 mg, 
those with ADD of 31–59 mg or 60 mg had signiﬁcantly higher total health care 
costs ($1835 and $5490, respectively, both p  0.05), while those with an ADD of 
30 mg had signiﬁcantly lower costs ($1853, p  0.05). CONCLUSIONS: Fibromy-
algia patients with an ADD  30 mg of duloxetine were more likely to adhere to 
therapy. Maintaining an ADD of 30 and 60 mg was associated with reduced total 
health care costs.
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OBJECTIVES: To determine ﬁbromyalgia (FM) prevalence in a french general popula-
tion setting, with a clinical conﬁrmation based on ACR criteria METHODS: This 
cross-sectional survey in a general population setting consisted in two steps: First, a 
telephone screening among 6,000 households using the French validated version of 
London Fibromyalgia Epidemiological Study Screening Questionnaire or LFES-SQ [1], 
then a rheumatologist’s conﬁrmation based on ACR criteria [2]. RESULTS: Of 3081 
polled subjects, 232 (7.5%) were screened positive ; 96 subjects accepted the consulta-
tion (41.4%), 70.8% were females. Mean age was 58.2 CI95 [55.2 ; 61.2] years. 
Finally 20 subjects (20.8%) met the ACR criteria, 17 were females. Mean age was 
56.9 CI95 [50.7 ; 63.1]. Thus FM prevalence is estimated to 1.5 % CI 95 [1.1; 2.0] 
based on the following algorithm : Prevalence (%)  [Ndiagnosis  (Ndiagnosis/Nconsultations 
 
Nrefusals)] 
 100/Nscreened patients NRefusals : screened positive patients who refused to 
consult, Ndiagnosis : conﬁrmed FM patients CONCLUSIONS: This 1.5% FM preva-
lence is consistent with other studies but lower than London Fibromyalgia Epidemio-
logical Study ﬁgures (2.7%)[1]. Those discrepancies can be attributable to patient’s 
easier access to specialists and a stricter physician’s interpretation of ACR criteria. [1] 
White KP. J Rheumatol 1999;26:1570–76; [2] Wolfe W. Arthritis & Rheumatism 
1990;33:160–72.
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OBJECTIVES: To estimate the annual and per-patient budget impact of the treatment 
of moderate to severe psoriasis in Greece before and after the introduction of 
ustekinumab. METHODS: A budget impact model was constructed from a National 
Health System perspective to depict the clinical and economic aspects of psoriasis 
treatment in a time frame of ﬁve years. It included drug acquisition, monitoring 
and administration costs for both the induction and maintenance years for patients 
treated with etanercept, adalimumab, inﬂiximab, with or without ustekinumab. It also 
considered the resource utilisation for non-responders. Greek treatment patterns and 
resource utilization data were derived from 110 interviews with dermatologists and 
an expert panel of 18 key opinion leaders of dermatology. Ofﬁcial published sources 
were used to derive the unit costs. Costs of adverse events and indirect costs were 
excluded from the analysis. The treatment response was deﬁned as probability of 
achieving a PASI 50, PASI 75 or PASI 90 response, based on published clinical trial 
data. RESULTS: The inclusion of ustekinumab in the biological treatment mix for 
moderate to severe psoriasis can lead to total per-patient savings of a481 and a1027 
in the ﬁrst and ﬁfth year of its introduction, respectively. The annual savings just on 
the hospitalisation costs of non-responders were estimated to be a900,000 in the ﬁrst 
year and a3 million in the ﬁfth. The cost savings were attributed to the reduced 
administration costs, reduced hospitalisations for non-responders, and improved efﬁ-
cacy. In an induction year and maintenance year (2-year period), there are a total of 
9 administrations for ustekinumab compared to 116 for etanercept, 54 for adalim-
umab and 15 for inﬂiximab. CONCLUSIONS: The inclusion of ustekinumab in the 
treatment of moderate to severe psoriasis in Greece is anticipated to have both short- 
and long-term health and economic beneﬁts both on an annual and per-patient 
basis.
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OBJECTIVES: The aim of the analysis was to estimate the budget impact of including 
new foods for special medical purposes (FSMP) for phenylketonutria (PKU) on the 
reimbursement list in Poland. Patients with phenylketonuria must adhere to phenyl-
alanine-restricted diet in order to prevent neurological impairment. METHODS: In 
2008 the reimbursement list in Poland included several FSMP; however, most of them 
were relatively old (basic portfolio). On the other hand, there were a lot of new PKU 
products not yet reimbursed (milupa pku2 prima, milupa pku2 secunda, milupa pku2 
shake, milupa pku3 advanta, milupa pku3 shake, milupa pku3 tablets, Minaphlex, 
Lophlex, Easiphen, XP_Maxamum). This analysis was performed from the public 
payer’s perspective (National Health Fund). A 5-year time horizon was adopted 
(2009–2013). The prognosis was based on the assumption that the PKU products sales 
in Poland will increase at the same rate as in the past few years. The market shares 
of speciﬁc PKU products were estimated based on data obtained from other European 
countries (scenario 1) and a questionnaire survey (scenario 2). The base scenario, 
assuming no changes on the reimbursement list, was also deﬁned. Total and incre-
mental costs were calculated. Incremental costs were deﬁned as the difference between 
scenario 1 (or scenario 2) and the base scenario. RESULTS: In the base scenario the 
total cost related to reimbursement of PKU products would amount to 23.95 million 
PLN in 2009 and 25.82 million PLN in 2013. In scenario 1, the expenditure for PKU 
products would increase by 0.3 million PLN in 2009 and 1.4 million PLN in 2013. 
In scenario 2 the expenditure would increase by 0.9 million PLN in 2009 and 2.9 
million PLN in 2013. CONCLUSIONS: This analysis showed that reimbursement of 
new PKU products would be associated with an incremental cost of about 3 million 
PLN.
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OBJECTIVES: Low dose 7-day buprenorphine transdermal patch (norspan®) is an 
opioid analgesic indicated in the management of chronic moderate to severe pain not 
responding to non-opioid analgesics. This patch has been marketed as products not 
covered by the national health insurance. The purpose of this analysis was to evaluate 
cost-effectiveness and budget impact of the buprenorphine patch, thereby assessing its 
eligibility for National Health Insurance coverage. METHODS: We carried out a 
cost-effectiveness analysis of the buprenorphine patches compared to tramadol tablets 
in patients with chronic, moderate to severe osteoarthritis (OA) pain, using a third-
party-payers perspective. The time horizon of analysis was 12-week. During this 
period, it was assumed that doses of study medication were titrated twice to achieve 
stable pain control. Patients’ global impression of pain relief was used as a clinical 
outcome variable, based on which we deﬁned good and very good pain relief as con-
trolled pain. Expert survey was conducted to investigate the treatment pattern and the 
cost of chronic pain. Budget impact analysis was applied to assess the impact of insur-
ance coverage of buprenorphine patches. Sensitivity analysis was performed for major 
parameters and possible scenarios. RESULTS: Buprenorphine patch was dominant 
compared to its comparator, displaying increased effectiveness and reduced costs. 
Budget impact analysis for 5 years indicated drug costs might increase by nearly 12.2 
billion won upon application of buprenorphine patch for insurance coverage; however, 
the budget for National Health Insurance including medical cost might decrease by 
nearly 2.9 billion won mainly due to decrement dispensing fee. Sensitive analysis sug-
gested that the most sensitive variable was the effectiveness of buprenorphine patches. 
CONCLUSIONS: Low dose 7-day buprenorphine patch was a cost-effective and cost-
saving alternative in the Korea National Health Insurance context. Study robustness 
needed more evidences about effectiveness.
